Verucerfont is a corticotropin-releasing factor receptor 1 ( CRF1 ) antagonist with IC 50 s of ~6.1, >1000 and >1000 nM for CRF1, CRF2, and CRF-BP, respectively.In VivoPost hoc analysis shows that the prototypic non-peptide CRF1 receptor antagonist NBI30775 (R121919) and Verucerfont are both significantly different from vehicle, CP-316 311, and pexacerfont (P<0.001 for all comparisons collapse across time-points); the latter three treatments in turn do not differ from each other. A differential effect of treatments over time is also shown by a significant treatment×time interaction (F[20,140]=6.4, P<0.001). Accordingly, detailed Post hoc analysis shows that both NBI30775 and Verucerfont inhibit ACTH release throughout the following 6 h of measurement (P<0.001 vs vehicle at each time-point, and vs the respective pretreatment baseline) . MCE has not independently confirmed the accuracy of these methods. They are for reference only.Form:SolidIC50& Target:IC50: 6.1 nM (CRF1), >1000 nM (CRF2), >1000 nM (CRF-BP). Specification: 0.99 Molecular Formula: C22H26N6O2 Molecular Weight: 406.48 PubChem CID: 11596613 Isomeric SMILES: CC[C@@H](C1=NC(=NO1)C)NC2=CC(=NC3=C(C(=NN23)C)C4=C(C=C(C=C4)OC)C)C
- UPC:
- 51181614
- Condition:
- New
- Availability:
- 4-8 weeks
- Weight:
- 1.06 Ounces
- HazmatClass:
- No
- WeightUOM:
- LB
- MPN:
- V647108-25mg
- CAS:
- 885220-61-1
- Product Size:
- 25mg
